Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Phillip Frost fined $5m by SEC for penny stock fraud
and the rest of his posse nicked too.
http://www.teribuhl.com/2020/03/09/sec-gets-penny-stock-bans-for-florida-men-in-honig-pump-dump-scheme/
Whoa, nice chart.
SEC suit: first move in a much wider crackdown
against a network of brokers, promoters and even attorneys
http://www.teribuhl.com/2018/09/12/laidlaw-execs-helped-barry-honig-execute-stock-manipulation-scheme/
No doubt, guy is a billionaire messing around with P&D garbage that might make him a couple million. What an idiot...
SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes
https://www.sec.gov/news/press-release/2018-182
WOW===> talk about GREED
he should be retired somewhere {{SMH}}
Garbage, sorry I set up this board...
Riot BlockChain CEO John O'Rourke is out, interim CEO is named in wake of unrelated SEC charges
The CEO and chairman of Riot BlockChain has resigned in the wake of unrelated charges by the SEC against him for alleged fraud.
John O'Rourke who has been the company's CEO since November 3, has been replaced by Chris Ensey and the new chairman of the board is Remo Mancini.
Jennifer Schlesinger | Scott Zamost | Hannah Kliot | Ritika Shah
Published 6 Hours Ago Updated 6 Hours Ago
CNBC.com
John O'Rourke (right) CEO of Riot Blockchain after a shareholders meeting in Oklahoma City on May 9, 2018.
Source: CNBC
John O'Rourke (right) CEO of Riot Blockchain after a shareholders meeting in Oklahoma City on May 9, 2018.
The CEO and chairman of Riot BlockChain has resigned in the wake of unrelated charges by the U.S. Securities and Exchange Commission (SEC) against him for alleged fraud in connection with other companies.
John O'Rourke who has been the company's CEO since November 3, has been replaced by Chris Ensey and the new chairman of the board is Remo Mancini, the company said in a new release issued Saturday.
The release did not specify a reason for the resignation, but Riot was not part of the SEC complaint. O'Rourke did not immediately respond to CNBC's request for comment.
Barry Honig, a Florida investor who was once Riot's largest shareholder, was also named in the SEC complaint.
The SEC announced on Friday charges against a group of 10 individuals and their associated entities for long-running fraudulent schemes that brought in more than $27 million.
The SEC called those charged "microcap fraudsters" in a press release.
"Honig was the primary strategist, calling upon other Defendants to buy or sell stock, arrange for the issuance of shares, negotiate transactions, or engage in promotional activity," according to the SEC complaint.
"In each scheme, Honig orchestrated his and his associates' acquisition of a large quantity of the issuer's stock at steep discounts, either by acquiring a shell and executing a reverse merger or by participating in financings on terms highly unfavorable to the company," it added.
The SEC brought the action for "three highly profitable 'pump-and-dump' schemes perpetrated by Honig, [John] Stetson, [Michael] Brauser, O'Rourke, [Mark] Groussman, and [Phillip] Frost, and their entities," the complaint alleged. Frost is a well-known biotech investor and founded Opko Health.
CNBC reached out to all those named in the complaint, but Groussman declined to comment while the other defendants were not immediately available. The SEC also alleges the defendants arranged and paid for stock promotion.
"Honig then directed O'Rourke to write a promotional article, which O'Rourke published under the pseudonym 'Wall Street Advisors' on Seeking Alpha," the complaint said. "[O'Rourke] also knowingly and falsely claimed 'not receiving compensation'" for writing the article.
In another instance cited by the SEC, John Ford, also a defendant, allegedly failed to disclose in an article promoting a stock that he had been compensated by Honig for writing the article, with Honig selling him below-market shares.
Riot Blockchain is a cryptocurrency company whose stock price skyrocketed after it changed its name.
Riot's stock was down more than 24 percent in after-market trading on the news.
Frost involved in P&D lawsuit -
Details and discussion here:
https://investorshub.advfn.com/SCAMS-R-US-25227/
Whoop, been watching that hoping this is the "The One" for Honig and hopefully would shine a brighter light on Brauser and the rest of those ass clowns.
It appears the SEC is finally on his trail. . .
"According to insiders who saw the SEC subpoena, a large portion of the regulator’s questions are about Honig, his company GRQ Consultants, and people who invest with him. I can also confirm Honig has been calling SEC enforcement defense lawyers this week looking for representation."
http://www.teribuhl.com/2016/09/23/investor-barry-honig-target-of-sec-mgt-capital-subpoena/
Be afraid when you see Honig in a Frost investment, be very afraid.
Another Dr. Frost Stinker
TRKK down from over a dollar to .07 since the first of the year. . .down from .30 when its latest pump started a couple of weeks ago. Yet, Honig and Brauser like to pump his involvement and still claim he only involves himself with winners.
http://www.gurufocus.com/news/405316/billionaire-investment-sparks-rapid-growth-in-orbital-tracking-
CDXC: Niagen will now be in Whole Foods, Vitamin Shoppe, Sprouts, Mothers Market and Vitamin Cottage
This is big news for CDXC boys
KAE
WOW! CDXC and P&G (Proctor & Gamble) article
P&G inks deal with maker of age-defying ingredient
Barrett J. Brunsman Staff reporterCincinnati Business Courier
Related Content
Former P&G president joins Target board
P&G’s breakthrough research could help cure these diseases
Two top P&G beauty execs land jobs with Coty
Home of the Day
Restored Licking Riverside Historic District BeautySponsor Listing
Restored Licking Riverside Historic District Beauty
See All Homes of the Day
P&G products include Olay Total Effects Anti-Aging Moisturizer. The company entered into a joint development agreement with the California maker of an ingredient that supposedly could help consumers ward off the effects of aging that would be used in existing and future products.?
Procter & Gamble Co. has entered into a joint development agreement with the California maker of an ingredient that supposedly could help consumers ward off the effects of aging.
ChromaDex Corp. said the deal involved a new proprietary ingredient called Niagen nicotinamide riboside that the Cincinnati-based company (NYSE: PG) would have the exclusive right to use in its products.
P&G products include Olay Total Effects Anti-Aging Moisturizer. The company entered into a joint development agreement with the California maker of an ingredient that supposedly could help consumers ward off the effects of aging that would be used in existing and future products.?Enlarge
P&G products include Olay Total Effects Anti-Aging Moisturizer. The company entered… more
Courtesy of P&G
Frank Jaksch Jr., founder and CEO of ChromaDex (OTCQX: CDXC), didn’t specify what P&G brands that Niagen NR might be used in, but a filing with the Securities and Exchange Commission indicated they could include existing and new products.
“This agreement positions our innovative new ingredient to be included in a number of P&G products, some of which are among the highest-volume consumer products in the world,” Jaksch said in a statement issued by the company based in Irvine, Calif.
Sponsored by
People on the Move
Matt Olliges
Matt Olliges
Zalla Companies
Myke Amend
Myke Amend
Lohre & Associates, Inc.
Chase Linkous
Chase Linkous
Messer Construction Co.
See More People on the Move ?
A spokesman for P&G declined to comment, citing competitive reasons.
P&G made an undisclosed payment to ChromaDex and will make other payments based on reaching various goals, according to the SEC filing. The companies will work together to identify and develop stable forms of Niagen NR, and over the next two years P&G will cover the cost, including human clinical studies and consumer research.
ChromaDex, which was founded in 1999, markets itself as an innovator in proprietary health, wellness and nutritional ingredients that can be used in everything from dietary supplements to skin care and pharmaceutical products.
P&G’s brands include Olay skin care, Meta Health Bar fiber supplements and over-the-counter medicines such as Prilosec OTC, which combats heartburn.
Procter & Gamble already claims its Pantene AgeDefy shampoo “counteracts the signs of aging hair,” and the company attributes similar youth-instilling properties to its Olay Age Defying Body Wash with Vitamin E.
ChromaDex’s portfolio of patented ingredients includes Niagen nicotinamide riboside, which is already being used as a dietary supplement marketed as Niagen NR Age Defense. The company claims the product is the first commercially available type of nicotinamide riboside, a form of vitamin B3 found in milk. ChromaDex thinks the ingredient could help delay or reverse the effects of aging as well as obesity and disease.
ChromaDex has touted the potential of Niagen NR in several news releases this year. In February, the company announced the initial results of the first human clinical study for Niagen NR had met its primary endpoint.
“The joint development agreement with P&G is a significant milestone in the commercialization of our leading breakthrough ingredient,” Jaksch said.
CDXC NEWS (Doc invests and deal with P&G)
Deal announced with Proctor and Gamble this morning
IDI - The Building Of An Extraordinary Business
http://seekingalpha.com/article/3598016-idi-the-building-of-an-extraordinary-business?app=1&auth_param=5p93j:1b2kf6r:4aa5a935d254cdd185884ebe9d22cadd&uprof=44
Today's GNC news is GREAT for CDXC
Chromadex (CDXC) will become the standard in this business for validating (core business) what is in supplements.
Hold GNC as it will bonce back.
Load up on CDXC here
KAE
I tried posting my thoughts on DIS.
As I completed that and posted it, all hell broke loose. And when the smoke cleared there were no message remnants at all as my post just seemed to disappear into j-space because iHub has no provisions to post into the shadow of what was once your message. All I saw was a raised flag with a message announcing that I can’t post to a message that doesn’t exist. Okay, I accept that, but the least they could do would be to preserve my message in the editor box. DIS at that time (which I think was late morning) was still all green but had a fairly large upper shadow, meaning it was very reluctant to go any higher. I anticipated the whole pattern to go flat going into earnings -- i.e. consolidate in some sort of flag or pennant. My plan if it should produce a healthy consolidation, which I suspect it will, is to buy Calls either prior or after breakout depending on how it looks. I guess a true pattern trader would wait till after it breaks out, but I am impressed with its orderly and linear climb through a very dense 8-point range of resistance during a much more hesitant market as depicted by $SPX.
Disney hasn’t broken through resistance. It could tomorrow, but my thoughts were that I don’t think it will. It’s earnings are due Nov 5 (a couple weeks away) and normally that nearness is sufficient to cause a stock to hesitate. I expected that early this morning, and I still do. Just have to wait and see. If it does, then it forms a flag or pennant pattern.
My impression is that price will continue to rise, and the rate will depend on earnings. My inclination would be to buy Nov 27, $110 Calls with no spread. That expiration would be 22 calendar days after earnings release. Depending on earnings, that’s sufficient for another 10-point rise which could happen as quickly as the last 10 points. Sometime during that time might be a good time to sell Nov $120 Calls (making it a belated spread), and use some of those proceeds to buy farther out Calls if it appears it could have legs, or to buy some Puts if it appears that it could fall back a little after having gone up 20% over a relatively short period.
Or, sometimes I think I don’t have a clue.
Yea, that's what I was suggesting...someplace where we can exchange ideas on trades and not be labeled "off topic" and I wasn't saying you should be a mod, just that your knowledge and input will be very educational to a few I know are desperate for guidance there. The concept of the board is a good one and "SwingKing" used Elliot Waves in his charting and analysis. I don't know how accurate he was on commodities he used them for I know I lost my ass on GDX and NUGT a couple of times but I guess that's the way it goes sometimes.
By the way...DIS has broken resistance or what? I guess the week's end will tell.
s_bux_
I only pay for things I consider worth supporting. So, no, I'm not a paying member. And this joint doesn't believe in free speech, so I can't support that either.
The mod (and probably the assistant) at that other board where your message was deleted is a mental case.
I've had enough control in my earlier life, so I have no desire for that anymore, especially if I'm not going to get paid for it. So you'll never see me as a mod or assistant anywhere.
I was trying to post something about DIS because I have a plan for it myself, and I'm somewhat impressed with its price action. Unfortunately my post got wiped out 'cause duh system doesn't know what to do with a post sent to something that just got deleted (your message). So, as I had no copy (which is unusual), I didn't feel like reconstructing it.
The board you suggest (... Elite-Swing ...) has a moderator and assistants listed, but I guess you mean they no longer show up. Perhaps you should request control of it -- I'm not interested. Then you should be able to get rid of those other characters if they are not active. It at least has a generic name so no du...ss moderator control freak can delete things for being 'off topic'.
Aside from my regular email address (which only personal friends get) I keep temporary, transient gmail addresses which I post publicly once in a while. Once abused, they're gone and I make a new one.
Actually since you're not a paying member I couldn't PM you to ask for your email as I assumed you wouldn't want to post it publicly. However, there is my moniker at gmail.com if you care to exchange ideas or there's this board which I'm certain you'll be a fine addition to as the creator seems to have vanished without a trace.
http://investorshub.advfn.com/Elite-Swing-Trades-25941/
You've had posts deleted.
Maybe you should start a new board?
It would be a good idea.
DIS?
COCP, Hep C drug selected and to start trials in 2016. News is on the AALSD abstract to be presented in Nov
ROX played well off $1 support w those insiders buys. If market tests again I would def buy at $1
SVON presented data today.
No position.
http://www.seviontherapeutics.com/sevion-therapeutics-presents-antibody-discovery-platform-at-international-conference/
CDXC up on volume last few days. Frosts buddy Honig taking a position.
Damn there's been a lot of open market buys at Castle Brands.
CDXC HUMAN TRIAL RESULTS: GAME CHANGER
Hey Little Boys: This is a GAME CHANGER for CDXC
BUY AS MUCH AS YOU CAN
KAE
MBVX is contracted to supply JUNO. Not sure why JUNO doesnt just aquire. Looking like MBVX may uplist; however would need to R/S to do so. High risk to buy at this level. I took the gamble though. Safer to buy at $2.50ish, support. Or wait for R/S.
please see my earlier post of a few days ago, I raised the same issue. Other than this board there doesn't seem to be anything linking KDUS with Frost.
I posted just now in the COCP board (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115999993) and would like to extend that post into a discussion about Frost's possible moves. In addition to COCP, three of Frost's stocks intrigue me: MBVX, SVACF, and SVON.
Cocrystal (COCP): High-mutating viral diseases and small-molecule antiviral drugs
Mabvax (MBVX): Cancer and human antibody-based products
SciVac (SVACF): Infectious and immune diseases and recombinant biological products
Sevion (SVON): Cancer and immunological diseases and antibody technology platforms
And of course the Frost marketing arm, OPK.
Does anyone have thoughts about combining vs not combining companies?
Kind regards,
Minding
Great article on SVACF and COCP and Dr. Frost
Go to the news under SVACF and pull up the story. It's a great story on Dr. Frost and the Hep space (both Hep C and Hep B). I think there is huge upside in both SVACF and COCP.
Kelly
Sevion Therapeutics, Inc. ("Sevion" or the "Company") (SVON) today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the “Offering”) whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963.
Each share of the convertible preferred stock is initially convertible into 10 shares of common stock. The warrants will have an exercise price of $1.50 per share, and will expire 30 months from the closing date, though they are exercisable in whole or in part at any time prior to expiration.
Laidlaw & Company (UK) Ltd. acted as placement agent for the Offering.
Investors in the Offering included certain affiliates of the Company’s Board of Directors (the “Board”), including Opko Health, Inc., of which Dr. Phillip Frost, a member of the Company’s Board, is Chief Executive Officer and Chairman.
KDUS: This sounds interesting and I appreciate the lead. There is no confirmation of Frost's involvement at Insider Trading going back to January 1, 2000.
Here's KDUS:
http://insidertrading.org/?sort_by=acceptance_datetime&asc=&symbol=kdus&date_from=2000-01-01&date_to=2015-08-03&submit=+GO+
Proof that the site works, here's COCP:
http://insidertrading.org/?sort_by=acceptance_datetime&asc=&symbol=cocp&date_from=2000-01-01&date_to=2015-08-03&submit=+GO+
If anyone has a link accessible to everyone (not just subscribers) that documents Frost's involvement with KDUS, please provide it.
Many thanks and kind regards,
Minding
FYI SVON has one of the past top guys from ImClone systems running it....fyi Imclone got bought by Eli Lilly for 70.00 a share in 2008
SVON Frost buys more....very bullish for this tiny microcap stock.Frost also has bought most above 2.00. Compare SVON with COCP and you see svon is massively undervalued
http://finance.yahoo.com/q?s=svon&fr=uh3_finance_web&uhb=uhb2
WSJ article about Dr. Frost play DRNE
WALL STREET JOURNAL ARTICLE ABOUT DRONE AVIATION (DRNE)
http://www.wsj.com/articles/some-drones-are-put-on-a-leash-1438557495?mod=pls_whats_news_us_business_f
Wow! Wow! WSJ article about DRNE! Unbelievable! Wall Street Journal!
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
416
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators starbuxsux |
Dr. Frost's brilliance
Dr. Frost was chairman at Mt. Sinai Medical Center in Florida and a consultant at Miles Laboratories when he met the manager, Michael Jaharis. They learned of a pharmaceutical company that had just lost $700,000 and couldn't afford to bring out a new drug.
Dr. Frost figured they could customize a new delivery system to effectively speed past the typical decade-plus drug commercialization route involving tens of millions of dollars. He invested $50,000 in the company, Key Pharmaceuticals, and found a new way of delivering an existing drug into the body.
Next, Dr. Frost and Mr. Jaharis took on a crotchety asthma medication. Theophylline was a little-used older drug, ineffective in small doses but toxic in large doses. So, Key researchers devised a way to incorporate the drug into a 12-hour time-release pill.
Blessed with good luck and good leadership, Key continued its unique pathway. The company didn't have the roughly $30,000 needed to test the pill but The University of Florida agreed to test it and publish the results. Rather than spending a lot of money on marketing, Key offered allergists pill samples backed by scientific data and a calculator to figure accurate dosage.
With successful drugs marketed, agreements with larger pharmaceutical companies followed. The realization hit the partners in 1986: They had, indeed, found the key to building a $50,000 straggler into a behemoth. They sold Key Pharmaceuticals to Schering-Plough for $800 million.
In 1987, Dr. Frost jiggled the key to open up the potential of generic products company Ivax. The company became the world's largest maker of low-priced copies of brand drugs whose patents had expired. The business was tough and disheartening at times - like the time a lucrative Norwegian merger fell apart in 1995. But Dr. Frost shoved away that disappointment.
He sold the business in 2005 to Teva Pharmaceutical Industries for a cool $7.6 billion.
The doctor from Miami Beach, Fla. continued his magic as he began building Opko Health in 2007. Today, the pharmaceutical and diagnostic company boasts a $4 billion market cap and a respected chief executive.
"Every company we've built has always had skeptics," he said. "And they have always paid the price in the end."
Dr. Frost indicated OPK is targeting multiple medical markets worth about $30 billion. We wouldn't be surprised if, at some point, Dr. Frost's company becomes an acquisition target of a large pharmaceutical company searching for promising drugs to replace its drugs with expiring patents.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |